Revance Therapeutics Stock (NASDAQ: RVNC) stock price, news, charts, stock research, profile.
Open | - |
Close | - |
Volume / Avg. | 937.000 / 1.777M |
Day Range | - - - |
52 Wk Range | 3.610 - 37.980 |
Market Cap | $396.019M |
P/E Ratio | - |
Dividend Yield | - |
Exchange | NASDAQ |
RSI | 30 |
Short Interest | 14.93% |
Days to Cover | 8.72 |
Name |
---|
Revenue Change |
Gross Change |
EBITDA Change |
EBIT Change |
Earnings Change |
You can purchase shares of Revance Therapeutics (NASDAQ: RVNC) through any online brokerage.
Other companies in Revance Therapeutics’s space includes: Atea Pharmaceuticals (NASDAQ:AVIR), Third Harmonic Bio (NASDAQ:THRD), Theravance Biopharma (NASDAQ:TBPH), GH Research (NASDAQ:GHRS) and SNDL (NASDAQ:SNDL).
The latest price target for Revance Therapeutics (NASDAQ: RVNC) was reported by Goldman Sachs on Friday, March 1, 2024. The analyst firm set a price target for 9.00 expecting RVNC to rise to within 12 months (a possible 136.84% upside). 29 analyst firms have reported ratings in the last year.
The stock price for Revance Therapeutics (NASDAQ: RVNC) is $3.8 last updated Today at April 24, 2024 at 8:47 AM EDT.
There are no upcoming dividends for Revance Therapeutics.
Revance Therapeutics’s Q1 earnings are confirmed for Tuesday, May 7, 2024.
There is no upcoming split for Revance Therapeutics.
Revance Therapeutics is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.